Filing Flows › Cencora (COR) › Guidance & outlook
Cencora (COR) guidance and outlook
Cencora (COR) raised its guidance on Nov 4, 2026: EPS $19.40–$19.75 for FY2027; EPS +8% to +10% for FY2027; Revenue +3% to +5% for FY2027; Revenue $337.4B for FY2027. Cencora's 10-Q filed Aug 5, 2026 makes 9 forward-looking statements, 0 of them new and 0 no longer said since the filing before.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| EPS | FY2027 | $19.40–$19.75 | new |
| EPS | FY2027 | +8% to +10% | new |
| Revenue | FY2027 | +3% to +5% | new |
| Revenue | FY2027 | $337.4B | new |
| Operating income | FY2027 | +4% to +6% | new |
| Operating income | FY2027 | $4.8B | new |
| Interest expense | FY2027 | $490M–$510M | new |
| Tax rate | FY2027 | 20% | new |
| Free cash flow | FY2027 | $3.5B | new |
| Capital expenditures | FY2027 | $1.0B | new |
| Operating income | long-term | +7% to +10% | raised |
| EPS | long-term | +10% to +14% | raised |
From the earnings release filed Nov 4, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Aug 5, 2026
- The annual LIFO provision, which we estimate on a quarterly basis, is affected by manufacturer pricing practices, which may be impacted by market and other external influences, expected changes in inventory quantities, and product mix, many of which are difficult to predict.
- Our primary ongoing cash requirements will be to finance working capital, fund the repayment of debt, fund the payment of interest on debt, fund the payment of dividends, fund purchases of our common stock, finance acquisitions, and fund capital expenditures and routine growth and expansion through new business opportunities.
- We currently expect to invest approximately $900 million in capital expenditures during fiscal 2026.
- We anticipate that we will continue to pay quarterly cash dividends in the future.
- updated · Our accrued litigation liability related to the Distributor Settlement Agreement, as well as other opioid-related litigation for which we have reached settlement agreements on our Consolidated Balance Sheet as of June 30, 2026 is $4.2 billion and is expected to be paid over the next 13 years.
- updated · We currently estimate that $396.2 million will be paid prior to June 30, 2027.
- The payment of the aforementioned litigation liability has not and is not expected to have an impact on our ability to pay dividends.
- However, there are no assurances that such instruments will be available in the combinations we want and/or on terms acceptable to us.
- Deterioration of general economic conditions, among other factors, could adversely affect the number of prescriptions that are filled and the amount of pharmaceutical products purchased by consumers and, therefore, could reduce purchases by our customers.
Cencora's latest quarter
Cencora, Q3 FY26: revenue $84.8B (+5% year over year), operating margin 1.3%, net earnings $777M, operating cash flow $2.7B. The chart follows the revenue to costs, profit and cash.
Questions
Did Cencora raise or lower its guidance?
Cencora (COR) raised its guidance on Nov 4, 2026: EPS $19.40–$19.75 for FY2027; EPS +8% to +10% for FY2027; Revenue +3% to +5% for FY2027; Revenue $337.4B for FY2027.
What does Cencora expect?
Our accrued litigation liability related to the Distributor Settlement Agreement, as well as other opioid-related litigation for which we have reached settlement agreements on our Consolidated Balance Sheet as of June 30, 2026 is $4.2 billion and is expected to be paid over the next 13 years. We currently estimate that $396.2 million will be paid prior to June 30, 2027.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.